NEWS DETAIL

礼来公司的 Jaypirca(吡托布替尼)在既往接受过治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 患者中,与维奈托克限时治疗方案联合使用,可显著降低疾病进展或死亡风险达 45%——PR Newswire

礼来公司的 Jaypirca(吡布替尼)在既往接受过治疗的 CLL/SLL 患者中,与维奈托克限时治疗方案联合使用,可显著降低疾病进展或死亡风险达 45%。——PR Newswire

医药资讯

该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Produk Berkaitan Artikel Ini

Produk ini dipadankan secara automatik berdasarkan tajuk, ringkasan, dan kandungan artikel.

Soalan Lazim

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Venetoclax – Beli dalam talian VECLADX Venetoclax 100mg Lucius Tazemetostat – Beli dalam talian Lucius Acalabrutinib – Beli Dalam Talian.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat